+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the efficacy, safety, tolerability, immune response, and how the body processes PRX-115, a recombinant pegylated Uricase, in adults with gout who have difficulty lowering their serum uric acid levels with standard treatments. This phase II, randomized, double-blind, placebo-controlled study also examines the effects of combining PRX-115 with methotrexate MTX, an immunomodulator, compared to placebos. The trial aims to find the best dosing schedule for intravenous PRX-115 infusions over 24 weeks. Participants are randomly assigned to receive PRX-115 infusions intravenously on different schedules every 4 weeks for six doses, every 6 weeks for four doses, or every 8 weeks for three doses. Some groups receive PRX-115 with oral MTX at 15 mg weekly, while others receive PRX-115 with a placebo MTX or placebo infusions with placebo MTX. This parallel design allows comparison of different dosing regimens with and without MTX. The treatment period lasts 24 weeks with multiple infusions according to the assigned schedule. During the study, participants undergo regular monitoring including blood tests to measure serum uric acid levels and safety assessments. Researchers track the percentage of participants achieving serum uric acid below 6 mgdL at six months as the primary outcome, along with other time-point measurements and treatment-emergent side effects. The study includes up to 8 months of follow-up to assess safety and tolerability. Participants health status, immunogenicity, pharmacokinetics, and pharmacodynamics of PRX-115 are also evaluated throughout the trial.

Age: 18Years +All GendersPhase 2
35 locations
P

Actively Recruiting

Researchers are evaluating CARTISTEM, a new treatment made from stem cells derived from donated umbilical cord blood combined with a gel, to determine if it is safer and more effective than a standard surgical procedure called debridement for people with knee cartilage damage and osteoarthritis. This Phase 3 trial aims to show if CARTISTEM can reduce knee pain and improve function better than debridement two years after treatment. The study also investigates whether CARTISTEM may slow osteoarthritis progression using MRI scans. Participants will be divided into two groups one will receive CARTISTEM combined with debridement surgery, where the stem cell gel is placed into the damaged knee area after bone stimulation. The other group will undergo debridement surgery alone, which removes damaged cartilage and smooths the knee tissue. CARTISTEM involves mixing stem cells and a gel before placing it in the knee during surgery. Both groups will be monitored over two years. During the study, participants will have assessments of knee pain using the Visual Analog Scale and knee function using the WOMAC index from enrollment through 24 months. MRI scans will measure cartilage repair and osteoarthritis progression. Participants must follow rehabilitation requirements and limit other knee treatments during the trial. The study includes randomization and double-blinding to compare outcomes fairly while monitoring safety and effectiveness over time.

Age: 18Years - 75YearsAll GendersPhase 3
35 locations
C

Actively Recruiting

Researchers are evaluating a diabetes education program tailored for Arab Americans with type 2 diabetes. This program, called Project Dulce Arabic, addresses cultural and language barriers that affect diabetes management in this community. It combines peer-led group education in Arabic and a 3-month text messaging support program. The study also explores the genetic background of type 2 diabetes in Arab Americans to increase awareness and improve prevention strategies. The intervention includes a 5-week peer-led curriculum covering diabetes knowledge, diet, exercise, medication, self-monitoring, and genetics. Afterward, participants receive ongoing support through Dulce Digital, a text messaging platform providing reminders and educational messages in Arabic. This combination aims to improve diabetes self-management behaviors and clinical outcomes such as hemoglobin A1C over three and six months. Participants will join the education sessions and receive text messages while researchers assess changes in diabetes knowledge, health beliefs, self-efficacy, and genetics understanding at 3 and 6 months. They will also track physical activity, diet, self-care activities, and hemoglobin A1C levels. The study involves blood tests and questionnaires to measure progress and gather genetic samples for research. The total participation includes ongoing monitoring throughout the study period ending in 2026.

Age: 18Years +All GendersPhase Not Applicable
2 locations